Companies / Vera Therapeutics, Inc.
Vera Therapeutics, Inc.
Nasdaq: VERACIK 1831828BRISBANE, CA
Financials
Ownership
72.1M shares outstanding · as of Jul 29, 2026
Ownership
| Insiders | 0.97% | 695,706 |
| 10%+ / strategic | 22.78% | 16,417,989 |
| Institutions | 87.60% | 63,124,512 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 13
View all →| Insider | % of shares | Shares |
|---|---|---|
Fordyce MarshallCEOPRESIDENT AND CEO · Director | 0.36% | 257,163 |
Grant SeanCHIEF FINANCIAL OFFICER | 0.16% | 114,181 |
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | 0.11% | 75,754 |
Skelton Laurence MatthewChief Commercial Officer | 0.09% | 64,218 |
Brenner RobertChief Medical Officer | 0.07% | 50,947 |
Johnson David LeeChief Operating Officer | 0.06% | 45,727 |
Turner William D.Chief Regulatory Officer | 0.06% | 45,313 |
Wright-Mitchell JaneChief Legal Officer | 0.06% | 42,403 |
Enright Patrick GDirector | — | — |
Hite ChristopherDirector | — | — |
Institutional holders 228
View all →| Holder | Value | % of shares |
|---|---|---|
| $298.21M | 8.17% | |
| $246.64M | 7.98% | |
| $180.81M | 4.95% | |
| $178.02M | 5.76% | |
| $173.85M | 4.76% | |
| $155.58M | 4.26% | |
| $149.74M | 5.17% | |
| $146.14M | 4.00% | |
| $142.86M | 3.91% | |
| $141.49M | 3.88% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Fordyce Marshall CEO | Sell | Class A Common Stock | $710.6K | -17K -6.17% | 257,163 0.36% of shares | medium |
| Feb 23, 2026 | Grant Sean Executive | Sell | Class A Common Stock | $207.8K | -5K -4.15% | 114,181 0.16% of shares | medium |
| Feb 23, 2026 | Young Joseph R Executive | Sell | Class A Common Stock | $130.9K | -3K -4.59% | 64,722 0.09% of shares | medium |
| Feb 23, 2026 | Johnson David Lee Executive | Sell | Class A Common Stock | $108.3K | -3K -5.34% | 45,727 0.06% of shares | medium |
| Feb 23, 2026 | Turner William D. Executive | Sell | Class A Common Stock | $91.8K | -2K -4.60% | 45,313 0.06% of shares | low |
| Feb 23, 2026 | Brenner Robert Executive | Sell | Class A Common Stock | $90.3K | -2K -4.05% | 50,947 0.07% of shares | low |
| Feb 23, 2026 | Skelton Laurence Matthew Executive | Sell | Class A Common Stock | $66.4K | -2K -2.40% | 64,218 0.09% of shares | low |
| Mar 13, 2026 | Young Joseph R Executive | Exercise | Class A Common Stock | $39.4K | +10K +15.21% | 75,754 0.11% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| State Street Corporation | Passive13G | — |
| Vanguard Group Inc | Passive13G/A | — |
| Vanguard Group Inc | Passive13G | — |
| Fmr LLC | Passive13G/A | — |
| T. Rowe Price Associates, Inc. | Passive13G/A | — |
| Deep Track Capital, LP | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| VERA | — | 92337R101 |